What is the ranking of selective serotonin reuptake inhibitors (SSRIs) by their serotonin transporter (SERT) binding affinity?

Ranking SSRIs by SERT Affinity

Based on binding affinity studies, escitalopram demonstrates the highest SERT affinity (Ki=1.1 nmol/L), followed by R-fluoxetine (Ki=1.4 nmol/L), with escitalopram being approximately 30-fold more potent than its R-enantiomer (R-citalopram) and representing the most SERT-selective compound among all SSRIs tested. 1

SERT Binding Affinity Hierarchy

The available pharmacological data establishes the following ranking from highest to lowest SERT affinity:

Tier 1: Highest Affinity

• Escitalopram (S-citalopram): Ki = 1.1 nmol/L
  • Most SERT-selective compound tested
  • 30-fold more potent than R-citalopram 1

Tier 2: High Affinity

• R-fluoxetine: Ki = 1.4 nmol/L
  • Unique among SSRIs with moderate affinity for 5-HT2C receptor (Ki=64 nmol/L) 1

Tier 3: Moderate Affinity

• Paroxetine: Moderate SERT affinity

  • Possesses moderate affinity (<50 nmol/L) for norepinephrine transporter 1
  • Less activating but more anticholinergic than other SSRIs 2

• Sertraline: Moderate SERT affinity

  • Possesses moderate affinity (<50 nmol/L) for dopamine transporter 1
  • Less effect on metabolism of other medications compared to other SSRIs 2

Lower Tiers

• Fluoxetine (racemic mixture)
• Fluvoxamine
• Citalopram (racemic mixture containing both S and R enantiomers)

Clinical Implications

Selectivity vs. Multi-target Effects: While escitalopram demonstrates the highest SERT selectivity, this does not automatically translate to superior clinical efficacy 3. Drugs affecting multiple transporters may provide different therapeutic profiles but can also result in additional adverse events 3.

Important Caveats:

• SERT binding affinity does not directly correlate with clinical effectiveness for depression or anxiety disorders
• The guidelines emphasize that SSRIs as a class share sufficiently similar primary mechanisms to warrant extension of findings across individual medications 4
• Choice of specific SSRI should be governed by pharmacokinetics, pharmacodynamics, tolerability, cost, and unique risk profiles rather than binding affinity alone 4

Pharmacokinetic Considerations: Both escitalopram and fluoxetine enter neurons within minutes while simultaneously accumulating in membranes at concentrations 18-fold (escitalopram) to 180-fold (fluoxetine) higher than applied concentrations 5. This membrane accumulation may play roles in therapeutic effects or discontinuation syndromes.